ntroduction: Cancer stem cells are recently noticed to contribute to tumor malignant behaviors, such as resistance to therapy and metastasis ability in tumors. On the other hand, it has been also known that tumor hypoxia is associated with such tumor malignancy. This indicates that tumor hypoxia might be a specific environment to keep up cancer stem cells within tumors. In this study, we examined relationships between existence of cancer stem cells and accumulation of hypoxia imaging agent 64Cu-diacetyl-bis (N4-methylthiosemicarbazone) (64Cu-ATSM) in vivo and conducted in vitro characterization. Methods: Double-tracer autoradiography and immunohistchemistry was performed with mouse colon carcinoma (Colon-26) tumor-bearing mice. In autoradio...
Institutions1.Molecular Imaging Center, National Institute of Radiological Sciences, Chiba, Japan.2....
Objectives: Radiolabeled Cu-diacetyl-bis (N4-methylthiosemicarbazone) (Cu-ATSM) is a potential PET i...
Introduction: Cancer treatment has evolved significantly, yet concerns about tumor recurrence and me...
ntroduction: Cancer stem cells are recently noticed to contribute to tumor malignant behaviors, such...
Objectives: 64Cu-diacetyl-bis (N4-methylthiosemicarbazone) (64Cu-ATSM) is a PET imaging agent target...
Introduction: 64Cu-diacetyl-bis (N4-methylthiosemicarbazone) (64Cu-ATSM) is a potential imaging agen...
Introduction64Cu-diacetyl-bis (N4-methylthiosemicarbazone) (64Cu-ATSM) is an imaging agent for posit...
64Cu-diacetyl-bis (N4-methylthiosemicarbazone) (64Cu-ATSM) is a promising theranostic agent targetin...
The purpose of this study is to reveal characteristics of 64Cu-labeled diacetyl-bis(N4-methylthiosem...
Cu-ATSM, a hypoxia imaging agent, effectively detects tumors due to the presence of hypoxia in solid...
Background: We studied the regional characteristics within tumor masses using PET tracers and immuno...
International audienceMapping tumor hypoxia is a great challenge in positron emission tomography (PE...
Intratumoral distribution of [Cu-64]Cu-diacetyl-bis (N4-methylthiosemicarbazone) (64Cu-ATSM) and flu...
(64)Cu-diacetyl-bis (N(4)-methylthiosemicarbazone) ((64)Cu-ATSM) is a potential theranostic agent ta...
2014 Spring.Includes bibliographical references.Oxygen status of tumors is an important clinical fac...
Institutions1.Molecular Imaging Center, National Institute of Radiological Sciences, Chiba, Japan.2....
Objectives: Radiolabeled Cu-diacetyl-bis (N4-methylthiosemicarbazone) (Cu-ATSM) is a potential PET i...
Introduction: Cancer treatment has evolved significantly, yet concerns about tumor recurrence and me...
ntroduction: Cancer stem cells are recently noticed to contribute to tumor malignant behaviors, such...
Objectives: 64Cu-diacetyl-bis (N4-methylthiosemicarbazone) (64Cu-ATSM) is a PET imaging agent target...
Introduction: 64Cu-diacetyl-bis (N4-methylthiosemicarbazone) (64Cu-ATSM) is a potential imaging agen...
Introduction64Cu-diacetyl-bis (N4-methylthiosemicarbazone) (64Cu-ATSM) is an imaging agent for posit...
64Cu-diacetyl-bis (N4-methylthiosemicarbazone) (64Cu-ATSM) is a promising theranostic agent targetin...
The purpose of this study is to reveal characteristics of 64Cu-labeled diacetyl-bis(N4-methylthiosem...
Cu-ATSM, a hypoxia imaging agent, effectively detects tumors due to the presence of hypoxia in solid...
Background: We studied the regional characteristics within tumor masses using PET tracers and immuno...
International audienceMapping tumor hypoxia is a great challenge in positron emission tomography (PE...
Intratumoral distribution of [Cu-64]Cu-diacetyl-bis (N4-methylthiosemicarbazone) (64Cu-ATSM) and flu...
(64)Cu-diacetyl-bis (N(4)-methylthiosemicarbazone) ((64)Cu-ATSM) is a potential theranostic agent ta...
2014 Spring.Includes bibliographical references.Oxygen status of tumors is an important clinical fac...
Institutions1.Molecular Imaging Center, National Institute of Radiological Sciences, Chiba, Japan.2....
Objectives: Radiolabeled Cu-diacetyl-bis (N4-methylthiosemicarbazone) (Cu-ATSM) is a potential PET i...
Introduction: Cancer treatment has evolved significantly, yet concerns about tumor recurrence and me...